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ABSTRACT
In an attempt to capture graft-versus-tumor effects without graft-versus-host disease (GVHD), the authors
initiated a trial of nonmyeloablative allogeneic bone marrow transplantation (BMT) in patients with advanced
hematologic malignancies, with the majority of patients having chemotherapy-refractory disease. Forty-two
patients received an HLA-matched related donor BMT after a cyclophosphamide and antithymocyte globulin–
based conditioning that also included thymic irradiation for patients who had not received prior mediastinal
radiotherapy. Prophylactic donor leukocyte infusion (pDLI) at a dose of 1  107 CD3 cells per kilogram were
given beginning 5 weeks post-BMT to 16 patients with mixed chimerism (MC) but without GVHD, whereas
26 patients did not receive pDLI, either because of GVHD or early relapse. Twelve of 16 patients (75%)
receiving pDLI had T cell chimerism at the time of pDLI >40%. These patients, by day 100 post-BMT, either
converted to full donor chimerism (FDC) (n 10) or had an increase in or stable donor chimerism (n 2) after
pDLI. Four of 4 patients whose T cell chimerism was<20% at the time of pDLI, lost the graft. In contrast, only
5 of 18 evaluable patients (28%) not receiving a pDLI converted to FDC by day 100 post-BMT, 7 maintained
MC, and 10 of an evaluable 22 lost the graft. Patients who had undergone a previous autologous stem cell
transplant had a higher rate of conversion to FDC (69% v 31%) and higher incidence of GVHD (69% v 34%)
compared with those who did not have a previous autologous SCT. Eleven of 16 patients (69%) who received
a pDLI achieved a remission with 50% 1-year progression-free survival rate and 44% 3-year overall survival
rate. Nineteen of 42 patients (45%) had >grade II acute GVHD, including 12 after BMT and 7 after pDLI.
Approximately one third of patients, after having initial MC, eventually lost their donor graft. The authors
conclude that (1) pDLI has the potential to convert MC to FDC; (2) sustained remissions can be achieved in
patients with chemorefractory hematologic malignancies who receive a pDLI, albeit with a significant risk of
acute GVHD; and (3) the degree of donor T cell chimerism at the time of pDLI is predictive of the fate of MC,
ie, donor T cell chimerism >40% or <20% at the time of pDLI correlates with conversion of MC or loss of
the graft, respectively.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
The prognosis of patients with advanced che-
morefractory hematologic malignancies is universally
dire. Whereas allogeneic SCT after myeloablative
conditioning has the curative potential for a fraction
of these patients, the treatment-related mortality rate
associated with this treatment is exceedingly high.
Alternative strategies, such as nonmyeloablative che-
motherapy and allogeneic SCT followed by donor
leukocyte infusion (DLI), currently are being evalu-
ated in patients with chemo-refractory hematologic
malignancies with the aim of achieving a durable an-
titumor response while reducing transplant-related
mortality.
Both experimental and clinical data indicate that
cell-mediated immunotherapy, known as graft-versus-
tumor (GVT) effect, plays a major role in the eradication
of disease in patients with hematologic malignancies
treated with allogeneic stem cell transplantation after
myeloablative conditioning [1-4]. The most striking and
direct evidence supporting the concept of a GVT re-
sponse was reported by Kolb et al. [5], who showed that
complete remission of relapsed chronic myelogenous
leukemia (CML) after allogeneic hematopoietic stem
cell transplantation could be achieved by simply infusing
donor leukocytes [6-8]. Subsequently, a GVT effect has
been shown convincingly in patients with lymphoma
[9-11], multiple myeloma [12-16], and chronic lympho-
cytic leukemia [17]. However, toxicities associated with
myeloablative conditioning as well as the occurrence of
signiﬁcant acute or chronic graft-versus-host disease
(GVHD) after therapeutic donor lymphocyte infusions
(DLI) remain substantial.
It has been shown that mixed lymphohematopoi-
etic chimerism can be achieved in mice across full
major histocompatibility complex barriers after both
myeloablative and nonmyeloablative preparative reg-
imens. These mixed chimeric mice are speciﬁcally
tolerant to donor and host antigens. When nontoler-
ant donor leukocyte infusions are given to these mixed
chimeras several weeks after bone marrow transplan-
tation (BMT), they convert to full donor-type chime-
ras as a result of a potent lymphohematopoietic graft-
versus-host reaction, but GVHD does not occur
[18,19]. Furthermore, delayed infusions of donor leu-
kocytes have been proven to mediate a powerful an-
titumor effect in murine fully allogeneic chimeras and
in mixed chimeras [20] without causing GVHD.
Thus, a delay in DLI in animals receiving a nonmy-
eloablative conditioning regimen can permit lympho-
hematopoietic GVH reactions, which are associated
with GVT effects, to occur without causing GVHD in
the nonlymphohematopoietic tissues. Based on the
principle of reduced transplant-related mortality asso-
ciated with nonmyeloablative conditioning therapy
and the attempt to maximize the GVT effect by de-
layed DLI, we have performed HLA-matched donor
transplants in patients with chemotherapy-refractory
hematologic malignancies using a nonmyeloablative
preparative regimen consisting of cyclophosphamide,
peritransplant antithymocyte globulin, thymic irradi-
ation, cyclosporine, and delayed prophylactic DLI
(pDLI). This nonmyeloablative allografting strategy is
novel in that it uses chemotherapy and vigorous host
and donor T cell depletion for the intentional induc-
tion of mixed chimerism (MC) as an immunologic
platform for DLI with the aim of separating GVHD
from GVT effects while maximizing antitumor reac-
tivity. Here we report the impact of pDLI on the
status of MC and its therapeutic potential in achieving
antitumor responses in patients with advanced lym-
phohematopoietic malignancies.
PATIENTS AND METHODS
Forty-two patients with advanced hematologic
malignancies, including 13 who had relapse after au-
tologous stem cell transplantation (AuSCT), received
an HLA-matched (at A, B, and DR loci) related donor
BMT between 1997 and 2001 based on a nonmyelo-
ablative MC protocol conducted at the Massachusetts
General Hospital in Boston. Patients showing no re-
sponse to chemotherapy after diagnosis or at the time
of relapse were considered to have treatment-refractory
disease (n  37; 16 in the pDLI group and 21 in the
non-pDLI group); those showing evidence of re-
sponse were considered to have chemosensitive disease
(n  2). Three patients underwent BMT without
being treated at the time of relapse and were said to
have untreated relapse at the time of the transplanta-
tion. Written informed consent was obtained from
each patient before enrollment on this Institutional
Review Board–approved protocol.
Patient Characteristics
The diagnosis, age, and disease characteristics for
the 42 recipients are shown in Table 1. The median
age of these 42 patients was 42.5 (range, 22 to 62)
years, and the median time from diagnosis to alloge-
neic BMT was 14 (range, 5 to 116) months. Eligibility
criteria included a diagnosis of chemotherapy-refrac-
tory hematologic malignancy, deﬁned as achievement
of less than a partial response or disease progression
during salvage chemotherapy or relapse after autolo-
gous stem cell transplants; Eastern Cooperative On-
cology Group performance status of 0, 1, or 2; age
65 years; and adequate organ function. Patients and
their donors were typed for HLA-A and HLA-B using
standard serologic techniques and for HLA-DR and
-DQ using sequence speciﬁc primer, or sequence spe-
ciﬁc oligonucleotide probe analyses. Based on their
disease status and previous therapy (eg, an autologous
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stem cell transplant), patients were believed to have a
prohibitively high risk of mortality after conventional
allogeneic stem cell transplantation or a very high risk
of posttransplantation relapse.
Treatment Protocol
Nonmyeloablative conditioning therapy consisted
of cyclophosphamide, 50 mg/kg/d, administered in-
travenously on 3 or 4 consecutive days on days 6 or
5 through 3; thymic irradiation (700 cGy) given
on day 1 in patients who had not received previous
mediastinal radiotherapy; antithymocyte globulin
(ATG), 15 to 30 mg/kg on days 2, 1, and 1 or
1, 1, 3 and 5; and cyclosporine beginning day
1 (5 mg/kg daily intravenously, reduced to 3 mg/kg
on day 4, switched to oral administration when tol-
erated at a dose of 6 mg/kg every 12 hours), then
tapered to discontinuation in the absence of GVHD
by 35 days post-SCT. The initial cohort of patients
(n  4) received a total of 200 mg/kg cyclophospha-
mide. For subsequent patients, the dose was reduced
to 150 mg/kg because of cardiac toxicity experienced
in 2 patients. The dose and schedule of ATG were
changed (currently 20 mg/kg on days 1, 1, 3 and
5) to reduce toxicities and achieve better in vivo
donor T cell depletion. Because of previous mediasti-
nal radiotherapy, 10 patients did not receive thymic
irradiation.
Bone Marrow Transplantation. A target number of
3  108 nucleated cells per kilogram of recipient body
weight was collected by marrow aspiration in the op-
erating room from donors under spinal, epidural, or
general anesthesia. In the case of minor ABO incom-
patibility, plasma was removed from donor marrow
before infusion, and in the case of major ABO incom-
patibility, red blood cells were depleted from the mar-
row using a CS-3000 cell separator (Baxter-Fenwal,
Round Lake, IL). The median number of nucleated
cells infused was 2.74  108 cells per kilogram of
recipient body weight (range, 0.6  108 to 12 
108/kg).
Donor Leukocyte Collection and Infusion. In the ab-
sence of clinically evident GVHD, patients were eli-
gible for pDLI, beginning on day 35 posttransplan-
tation in an effort to convert their mixed chimeric
state to a state of full-donor hematopoiesis. Unmobi-
lized donor leukocytes were obtained by leukapheresis
using a COBE Spectra cell separator (Cobe Labora-
tories, Lakewood, CO) according to the manufactur-
er’s instructions. Pheresis durations were 120 to 240
minutes and yielded a median of 1.4  108/kg recip-
ient body weight (range, 0.7 to 2.0) mononuclear cells
and 0.8  108/kg recipient body weight (range, 0.3 to
1.1) CD3 T cells. The target number of CD3 T
cells per infusion given to 16 patients for conversion
of MC to a state of full donor hematopoiesis was 1 
107/kg. In 4 instances, as part of the original protocol,
1 to 5 107 CD3 T cells per kilogram were given in
a second pDLI on or about day 56 posttransplant.
Higher numbers of CD3 T-cells (range, 1  107 to
2.98  108/kg) as therapeutic DLI (tDLI) were given
to 11 patients for treatment of progressive or relapsed
disease.
Supportive Care
Patients were cared for either in HEPA-ﬁltered or
laminar air ﬂow rooms. All patients had triple lumen
Silastic (Dow Corning, Midland, MI) central venous
catheters. Anti-infective measures included co-tri-
moxazole for Pneumocystis carinii prophylaxis from ad-
mission until day 1, then 3 times weekly after reso-
lution of neutropenia; levoﬂoxacin, 500 mg daily, until
resolution of neutropenia, ﬂuconazole beginning on
day1 at a dose of 400 mg, which was reduced to 200
mg daily on day 0; and intravenous acyclovir at a dose
of 250 mg/m2 every 8 hours beginning on day 1,
which was changed to a dose of 400 mg twice daily
after resolution of neutropenia. Febrile neutropenia
was treated with broad spectrum antibacterial agents
usually consisting of vancomycin and ceftazidime. All
blood products were irradiated with 2500 cGy using a
cesium irradiator and were transfused through a third-
generation leukocyte depletion ﬁlter. Initial treatment
of acute GVHD consisted of corticosteroids (methyl-
prednisolone), initially at a dose of 1 to 2mg/kg, then
tapered as tolerated.
Table 1. Patient Characteristics
Patient No. 42
Sex (M/F) 25/17
Median age (yr) 43
(range) (22-62)
Disease (%)
NHL 24 (57)
Intermediate grade 18 (75)
Low grade 6 (25)
HD 7 (17)
AML 4 (10)
ALL 1 (2)
CLL 3 (7)
MDS 1 (2)
MM 2 (5)
Related donor source (%)
HLA-genotypically identical 41 (98)
HLA-phenotypically identical 1 (2)
Sibling donors 41 (98)
Sex matched donors 33 (67)
No. of prior therapies median (range) 3 (1-7)
Time from diagnosis to BMT (d) 668
median (range) (150-3474)
Previous auto transplant (%) 13 (30)
NHL indicates non-Hodgkin’s lymphoma; HD, Hodgkin’s dis-
ease; AML, acute myloid leukemia; ALL, acute lymphoblastic leuke-
mia; CLL, chronic lymphocytic leukemia; MM, multiple myeloma;
MDS, myelodisplastic syndrome; BMT, bone marrow transplant.
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Analyses of Chimerism
Analyses of microsatellite variable number of tan-
dem repeat (VNTR) or short tandem repeat (STR)
markers were performed on peripheral blood leuko-
cytes from the patients and their donors before BMT.
Each assay included mixtures of pretransplant donor
and recipient DNA at different ratios, which were
used to estimate the percentage of donor or recipient
cells present in the posttransplant samples. For early
patients, CD3-enriched and CD3-depleted popula-
tions were isolated from the peripheral blood using
MACS beads (Miltenyi Biotec, Sunnyvale, CA). Re-
cently, granulocytes (myeloid cells) were isolated by
centrifugation over a density gradient (Isolymph, Gal-
lard Schlesinger, Carle Place, NY), after which CD3-
enriched cells (lymphoid cells) were isolated from the
mononuclear cell population using MACS beads.
Weekly microsatellite analyses were performed on
peripheral blood leukocytes beginning on day 7
through day 100 posttransplant and on days 28
and 100 on bone marrow aspirate samples.
Status of Remission
At approximately day 100 post-BMT, all evalu-
able patients underwent restaging evaluations includ-
ing computed tomography (CT) scans of chest, abdo-
men, and pelvis; a gallium scan when applicable; and
bone marrow aspirate and biopsy. Patients with no
evidence of disease based on these studies were deter-
mined to be in complete remission, and those with
more than 50% reduction in measurable disease were
considered to have achieved a partial remission. A few
patients with residual radiographic abnormalities on
CT scans were required to have a negative Gallium
scan as a criterion for complete remission (CR).
Evaluable patients underwent follow-up studies (CT
scans, Gallium scan, bone marrow examination as in-
dicated) every 6 months for at least 3 years after BMT.
Statistical Analysis
Descriptive statistics are summarized as a percent-
age or as the median and range where appropriate.
Comparison between groups of the analyzed parame-
ters were performed using Fisher’s exact test. A P
value of less than .05 was considered signiﬁcant. Over-
all survival and progression-free survival rates were
calculated using the Kaplan-Meier method.
RESULTS
Prophylactic versus Therapeutic Donor
Lymphocyte Infusions
In an attempt to convert a mixed chimeric state to
full donor chimerism (FDC) and achieve a putative
GVT effect, hopefully without clinical GVHD, 16 of
42 patients (38%) received pDLI at 1  107 CD3
cells per kilogram starting as early as 5 weeks post-
transplant (Table 2), including 4 patients (UPN 181,
Table 2. Outcomes of Patients Receiving Prophylactic-DLI
UPN
Diagnosis
(Age, yr)* AuSCT
% of Donor T cell
Chimerism pDLI
Time to
Chimerism
Conversion
(Days post-
BMT)
Acute
GvHD
(Grade) Response
PFS
(mo)
OS
(mo)Pre-pDLI Post-pDLI Day 1 Day 2
21 NHL (35) Yes 60 >99 35 84 No CR >52 Alive >52
181 NHL (41) 80 >99 35 56 73 IV CR 6 6
234 NHL (22) 50 >99 34 62 91 No CR >52 Alive >52
254 HD (27) 40 >99 36 57 82 IV PR 4 5
285 CLL (50) 95 >99 37 48 I CR 19 19†
317 NHL (39) 60 >99 35 55 III PD 2 3
322 NHL (50) 20 <1 36 64 No PR 14 Alive >38
328 NHL (61) 50 50 40 91 No PR 12 18
329 HD (55) Yes 40 99 41 91 I CR 11 11‡
334 HD (24) Yes 40 95 44 70 IV PD 1 3
349 CLL (45) 5 <1 42 No PD 2 Alive >34
360 HD (42) 5 <1 37 No CR >32 Alive >32
395 MM (51) Yes 95 99 35 42 II CR >25 Alive >25
402 NHL (43) 5 <1 36 No PD 2 13
403 NHL (57) Yes 80 99 36 68 IV CR >23 Alive >23
409 NHL (42) Yes 40 99 44 70 II PD 2 4
PD indicates progressive disease; NHL, non-Hodgkins lymphoma; HD, Hodgkin’s disease; AML, acute myeloid leukemia; ALL, acute
lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; MDS, myelodisplastic syndrome; AuSCT, prior
autologous stem cell transplant; PFS, progression-free survival; OS, overall survival.
*Age at the time of BMT.
†UPN 285 died of infection.
‡UPN 329 died of acute myocardial infarction; both were in CR at the time of death.
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234, 254, 322) who received a second pDLI (1  107
CD3 cells per kilogram, n  3; and 5  107 CD3
cells per kilogram, n  1) between days 56 and 64
post-BMT. CSA was discontinued 24 hours before
the administration of pDLI. Eighteen patients (43%)
did not receive the pDLI because of the emergence of
GVHD or initial suspicion of GVHD (Table 3).
Eleven of 42 patients (26%) were given tDLI(s) for
posttransplant disease progression (early progression,
n  8; late relapse, n  3).
Status of Chimerism
All patients had initial MC, deﬁned as more than
1% peripheral blood donor myeloid or T cells. Pa-
tients who had less than 1% donor chimerism in both
lymphoid (CD3) and myeloid (CD3) lineages were
declared to have lost their donor graft. Twelve of 16
patients (75%) receiving pDLI either converted to
FDC (n  10; 63%) with a median conversion time of
70 (range, 35 to 91) days post-BMT (or, median 32
days post-pDLI), or had increased or stable donor
chimerism (n  2) after pDLI by day 100 post-BMT,
whereas 4 of 16 (25%) patients lost the donor chimer-
ism despite pDLI (Table 2). In contrast, only 5 of 18
evaluable patients (28%; 8 patients who died within 2
months of BMT were removed from the analysis) who
did not receive a pDLI converted to FDC, with 4
converting spontaneously by day 100 post-BMT and
one converting only after tDLI; 7 patients maintained
stable MC, and 10 of 22 evaluable patients ultimately
lost their grafts in spite of early and late tDLIs.
Among 10 patients (out of 11 evaluable patients) who
received tDLI, 7 lost the donor graft, 2 maintained
MC, and one achieved FDC. Of 13 patients who
previously underwent an autologous stem cell trans-
plant 9 achieved DFC (69%), 3 had sustained MC,
and 1 lost the graft. In contrast, only 9 of 29 patients
(31%; P .02) who had not had a previous autologous
stem cell transplant achieved FDC (Table 4).
Table 3. Outcomes of Patients Not Receiving Prophylactic DLI
UPN
Diagnosis
(Age, yr)* AuSCT GVHD tDLI (d)
% of Donor T cell
Chimerism
Graft Loss
(d)
FDC
(d) Response
PFS
(mo)
OS
(mo)Day 28 Day 100
259 ALL (40) No No 50 NE PD <1 1
275 NHL (43) No No 10 43 CR 7 16
282 NHL (57) No Yes (35) 5 35 PD <1 2
283 AML (44) No Yes (38) 10 40 PD 1 13
344 NHL (35) No Yes (35) 50 NE PD <1 1
216 MDS (59) Yes No Yes (41) 20 61 PD 1 8
384 NHL (59) No Yes (35) 20 85 PD 1 12
410 HD (34) No Yes (44) 10 40 PD <1 4
160 MM (56) Yes II No >99 35 CR 12 Alive >20
194 NHL (44) I Yes (120) 1 28 PR 1 6
218 AML (44) I No 50 63 PD 1 2
351 HD (43) Yes I No 70 95 CR >34 Alive >34
358 NHL (57) I Yes (42) 80 50 PD 1 2
376 AML (58) I No NA NE PD <1 1
377 NHL (41) I No 40 34 PD 1 1
201 NHL (45) II No 60 93 PR 7 17
238 HD (27) Yes II Yes (371) 60 80 CR 9 34
268 CLL (55) II No 60 95 CR >46 Alive >46
279 NHL (62) II No 95 NE PD 1 1
368 NHL (36) Yes II No 90 92 PD 3 7
386 AML (57) II Yes (54) 40 89 PD 1 23†
396 NHL (36) II Yes (292) 70 95 PD 2 11
398 NHL (52) II No 80 80 CR >24 Alive >24
346 NHL (46) Yes III No 40 40 PD 2 3
352 NHL (38) Yes III No 80 45 PD 1 6
247 AML (27) IV No 60 80 CR 3 3
PD indicates progressive disease; tDLI, therapeutic donor leukocyte infusion; FDC, full donor chimerism; GL, graft loss; NHL,
non-Hodgkins lymphoma; HD, Hodgkin’s disease; AML, acute myloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic
lymphocytic leukemia; MM, multiple myeloma; MDS, myelodisplastic syndrome; AuSCT, prior autologous stem cell transplant; PFS,
progression free survival; OS, overall survival; NE, not evaluable.
*Age at the time of BMT.
†This patient with secondary AML had evidence of progressive disease within a month after BMT, converted to full donor chimerism after
tDLI with the achievement of sustained remission, but died of marantic endocarditis (in association with recurrent AML) 2 years after BMT.
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Level of Donor T Cell Chimerism at the Time of
pDLI as a Predictor of the Fate of Mixed
Chimerism Post-pDLI
As shown in Figure 1, all patients who underwent
conversion to FDC or had an increase in donor chi-
merism after pDLI had T-cell chimerism of 40%
(range, 40% to 95%) at the time of pDLI. All patients
whose T cell chimerism was 20% at the time of
pDLI lost their grafts post-pDLI. Five patients in the
non-pDLI group who underwent conversion to FDC
as well as 7 patients in this group who maintained
stable MC had 40% donor T cell chimerism during
the time frame when pDLIs were given to other pa-
tients (Table 3). However, by day 100 post-BMT the
conversion to FDC after pDLI in patients with40%
donor T cell chimerism at the time of the DLI was
higher (10 of 12; 83%) compared with non-pDLI
group, in which only 5 of 18 patients (28%) who had
40% donor T cell chimerism at approximately 35
days post-BMT achieved FDC. These results indicate
that the degree of donor T cell chimerism at the time
of pDLI was predictive of the fate of MC post-pDLI,
ie, donor T cell chimerism 40% or 20% at the
time of pDLI correlated with conversion of MC or
loss of graft, respectively.
Graft-versus-Host Disease
Twelve of 42 patients (29%) had grade II-IV acute
GVHD after the BMT (grade II, n 9; grade III, n
2; grade IV, n  1), and 8 of these patients achieved
remissions (Table 3). As shown in Table 2, 7 of 16
patients (44%) had grade II or above acute GVHD
after pDLI (grade II, n 2; grade III, n 1; grade IV,
n  4), with 4 achieving remissions (CR, n  3; PR,
n  1). Two of 4 patients (UPN 181, 254) who
received a second pDLI had grade IV GVHD with
conversion to FDC. Seven patients in the pDLI group
and 2 in the non-pDLI group achieved remissions
without GVHD or with grade I only GVHD (Table
4). Nine of 13 patients (69%) who had undergone a
previous autologous SCT had grade II or above acute
GVHD either after the BMT (n  5) or after pDLI
(n  4) in comparison with the entire series, in which
only 10 of 29 patients (34%) had GVHD (P  0.03),
suggesting that extensive prior therapy is a strong
predictor for the development of GVHD (Table 4).
Only 2 patients (UPN 181, 334) died of GVHD
(grade IV). Acute GVHD was staged and graded using
the Seattle criteria, as described [21].
Disease Response and Survival Outcomes
As is summarized in Table 5, 11of 16 patients
(69%) who received pDLI(s) achieved a remission
(CR, n  8; PR, n  3); 7 of these patients with a CR
underwent conversion to FDC, whereas one with a
CR eventually (by day 60) lost the graft. Nine of 26
patients (35%) in the non-pDLI group achieved a
remission (CR, n  7; PR, n  2); one with a CR
underwent conversion to FDC, 5 with a CR had stable
MC, and one with a CR lost the graft (Table 5). The
median overall survival rate of patients receiving pDLI
was 18 (range, 3 to 52) months with a 50% one-year
Table 4. Inﬂuence of Au-SCT on Mixed Chimerism and GVHD
Prior
Autologous
Transplant
(n  13)
No Prior
Autologous
Transplant
(n  29)
P
Value
FDC 9 (69%) 9 (31%) .02
GL 1 (7%) 11 (37%) .04
aGVHD 9 (69%) 10 (34%) .03
FDC indicates full donor chimerism; GL, graft loss; aGVHD,
acute graft-versus-host disease.
Figure 1. The pattern of donor T cell chimerism before and after pDLI, as determined by microsatellite analysis of peripheral blood performed
once weekly until day 100 post-BMT.
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progression-free survival rate (Figure 2B) and 44%
3-year overall survival rate (Figure 2A). Seven of 16
pDLI recipients, including 6 of 11 who achieved re-
mission, remained alive at a median of 2.5 (range, 1.5
to 4) years (Table 2; Figure 2A). Two patients died of
nonrelapse causes (myocardial infarction and infec-
tion; both were in CR at the time of death); 5 patients
died of relapsed disease and 2 of GVHD. One patient
(UPN 402) with non-Hodgkin’s lymphoma (NHL)
lost evidence of donor chimerism after nonmyeloab-
lative BMT, had recurrent disease, and underwent
myeloablative allografting. He then had bronchiolitis
obliterans with organizing pneumonia (BOOP) and
died of respiratory failure; autopsy showed no evi-
dence of lymphoma. One patient (UPN 349) with
chronic lymphocytic leukemia who lost the graft had
Richter’s transformation and underwent myeloabla-
tive allogeneic SCT followed by DLI for recurrent
disease; she remained in CR 14 months after the
second allogeneic transplant. In contrast, the median
overall survival rate was 6.5 (range, 1 to 46) months,
and 1-year progression-free survival rate was 15% in
patients who did not receive pDLI because of GVHD
or suspicion of GVHD or early relapse, regardless of
whether early or late tDLI(s) were given for disease
progression. Four of 26 patients (15%) in the non-
pDLI group remained alive at a median of 2 (1.4 to
3.5) years; 20 died of progressive disease, one died of
infection and one of GVHD and posttransplantation
lymphoproliferative disorder (PTLD). The 1-year
progression-free survival in the whole cohort of pa-
tients was 29% with an overall survival rate of 30% at
2 years (Figure 2A and B). Twenty-two of the total 42
patients did not achieve an antitumor response.
DISCUSSION
Because of multiple variables, including the design
and mission of the treatment strategy and the various
factors that determined whether patients received a
pDLI, the aim of this uncontrolled study was not to
compare the outcomes between the pDLI and non-
pDLI groups. Rather, we have focused on the patterns
of chimerism in patients who received this cyclophos-
phamide-based nonmyeloablative transplant strategy
with delayed DLI (pDLI) and the complications of the
transplants and DLI. This transplant strategy was a
direct translation of preclinical murine BMT studies
[19] in which the achievement of stable MC assures a
state of bidirectional, (ie, donor- and host-speciﬁc)
tolerance [18, 22-26] and thus can serve as an immu-
nologic platform for pDLI, which can convert the
mixed chimeric state to a state of full donor hemato-
poiesis via a GVH [18-20, 27]. In animal models, this
powerful GVH alloreaction against lymphohemato-
poietic cells has been shown to be capable of eradicat-
ing leukemia without causing clinically signiﬁcant
GVHD, even though donor T cells were given in
numbers that would cause rapidly lethal GVHD in
recipients who had just undergone radiation [20, 28].
The goals of our strategy were to deliberately
induce initial MC followed by the administration of
Figure 2. Kaplan-Meier (A) overall survival probability and (B)
progression-free survival probability and for the 16 patients who
received pDLI.
Table 5. Chimerism and Disease Response
FDC SMC GL
pDLI (n  16)
CR 7 1
PR 1 1 1
PD 2 1 2
Total 10 2 4
No pDLI (n  26)
CR 1 5 1
PR 1 0 1
PD 3 2 8/12†
Total 5* 7 10
FDC indicates full donor chimerism; SMC, stable mixed chi-
merism; GL, graft loss.
*Four of 5 patients had spontaneous FDC and one had FDC
after tDLI.
†Eight of 12 patients had evidence of loss of chimerism; 4
patients were not evaluable.
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pDLI as early as possible after BMT to capture the
maximal GVT effect, hopefully without the occur-
rence of GVHD [29,30]. Sixteen of 42 patients (38%)
who did not develop clinical GVHD after BMT had
their cyclosporine (the only posttransplant pharmaco-
logic immunosuppressive drug given) rapidly tapered
and received pDLI around 5 to 6 weeks after trans-
plant. A response was achieved in 11 of these 16
patients. This clearly indicates a powerful immune-
mediated antitumor effect, because most of these pa-
tients had previously shown resistance to cyclophos-
phamide, the only cytoreductive agent used in our
conditioning regimen. Twelve of 16 patients either
underwent conversion to FDC or had an increase in
or stable donor chimerism after pDLI, whereas 4 of 16
lost the graft post-pDLI. With rare exception, the
gradual achievement of complete remission after
pDLI was associated with progressive conversion to
FDC (Table 2), suggesting that a lymphohematopoi-
etic graft-versus-host response mediated the GVT ef-
fect, as has been observed in the mouse model [20,28].
The persistence of antitumor responses in these pa-
tients correlated with the presence of sustained en-
graftment, highlighting the importance of the pres-
ence of donor T cells for inducing and maintaining
the remission. One possible explanation for the po-
tency of this GVT mechanism may be the presence of
host-derived antigen-presenting cells (APC) in the
mixed chimeric state at the time of pDLI. Host APC
have been shown to be instrumental in eliciting GVH
responses in a murine model of minor antigen-mis-
matched BMT [31]. Recently, Mapara et al.[20]
showed in a murine leukemia model that GVT activity
mediated by DLI is markedly superior in mixed chi-
meras compared with full chimeras, and that host-type
APCs are important for the induction of maximal
GVT effects. It is clear that the mixed chimeric state
does not always reﬂect a state of tolerance, at least in
humans, because many patients (n  7) in the non-
pDLI group who had sustained MC had GVHD with
the achievement of CR (n  5). The remissions in 2
patients who rejected the graft even after pDLI (Table
2) is perplexing and raises the question of whether a
heightened immune-mediated host-derived antidonor
response played a role in this antitumor effect.
Clearly, the degree of donor chimerism, that is,
the presence of 40% donor T cells at the time of
pDLI, correlated with the conversion to increased or
complete donor chimerism. Conversely, 4 of 4 pa-
tients whose donor T cell chimerism was20% at the
time pDLI lost their grafts after pDLI. This is con-
sistent with the ﬁndings of Schattenberg et al. [32],
who recently showed that the percentage of donor T
lymphocytes correlated well with the outcome of
tDLI in relapsed patients after T cell–depleted BMT.
It is also interesting to note that 5 patients in the
non-pDLI group who underwent conversion to FDC
and 7 patients who had stable MC or increased DC
had 40% donor T cell chimerism at the time when
pDLI were given to other patients. These results sug-
gest that there may exist a threshold for donor T cell
chimerism post-BMT that dictates the fate of MC, ie,
donor T cell chimerism 40% or 20% at the time
(5 to 8 weeks posttransplant) of pDLI correlates with
conversion of MC or loss of graft, respectively. Ap-
proximately one third of our patients, after having
initial MC, eventually lost their donor graft, including
11 patients after prophylactic or tDLI. We recently
have obtained evidence that loss of chimerism in these
patients is caused by immune-mediated rejection. As
in most such patients, this rejection appears to be
mediated by an increased recovery of donor-reactive
recipient CD8 cells as well as interleukin-2 (IL-2)-
producing recipient T helper cells (A. Kraus and M.
Sykes, unpublished data).
The major cause of treatment failure in patients
with advanced lymphohematopoietic malignancies af-
ter nonmyeloablative allogeneic BMT has been early
progression of their underlying disease, presumably
caused by an insufﬁcient GVT effect from the BMT
alone in this group of patients with aggressive, often
bulky disease. Immunotherapy in our protocol is in-
tended to arise from the pDLIs, which were adminis-
tered as early as 5 weeks after BMT. In their nonmy-
eloablative strategy, McSweeney et al. [33] used 2
drugs for GVHD prophylaxis after BMT, and occa-
sionally they administered DLI only beyond 2 months
post-BMT. Although we have shown that early dis-
continuation of CSA with the administration of pDLI
is feasible in many cases, the incidence of grade II or
above GVHD after BMT and pDLI (45%) remains
substantial. This incidence of acute GVHD, however,
is similar to the experience described in other studies
[16,34]. At the Dana Farber Cancer Institute, pDLIs
were administered 6 to 9 months after T cell–depleted
myeloablative BMT in patients with multiple my-
eloma [16], whereas the Seattle group delivered the
ﬁrst DLI 56 to 326 days after nonmyeloablative BMT
in patients with hematologic malignancies [33]. Pos-
sible reasons for the presence of GVHD in several of
our patients include (1) the incomplete T cell deple-
tion of the donor marrow (by ATG) induced either
clinical GVHD after BMT or a subclinical GVHD,
which was accentuated when nontolerant pDLIs were
given; and/or (2) the proinﬂammatory conditions (up-
regulation of cell adhesion molecules and various cy-
tokines and chemokines) that play a role in the patho-
genesis of GVHD are different in heavily pretreated
patients and not as short lived in duration as in animal
models. In patients who had had a previous autologous
stem cell transplantation, both conversion to FDC
and acute GVHD were signiﬁcantly increased in com-
parison with those who did not have prior AuSCT
(Table 4), indicating that AuSCT is a predictor for the
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development of GVHD, probably because of pro-
found host immunosuppression caused by earlier ther-
apies [30]. Although the incidence of acute GVHD
was signiﬁcant, only 2 patients in the pDLI group died
of GVHD, including one who received 2 pDLIs ac-
cording to our original protocol. Five patients
achieved remissions with conversion of their MC with
no (n  3) or minimal grade I GVHD (n  2)
providing proof of the principle that lymphohemato-
poietic GVH reactions, with GVT effects, are sepa-
rable fromGVHD in humans, as in the mouse [20,28].
Remissions were seen in 20 of 42 patients (48%)
with advanced malignancies, including 9 of 26 in the
non-pDLI and 11 of 16 in the pDLI groups. Although
the treatment outcomes in these patients with ad-
vanced lymphohematopoietic malignancies are highly
encouraging, a comparison of survivals between pDLI
and non-pDLI groups is not possible because the
non-pDLI group may have been already preselected
for adverse outcome on the basis of early relapse.
Sustained antitumor responses were seen in both in-
dolent and aggressive histologies of NHL, Hodgkin’s
disease, chronic lymphocytic leukemia, and multiple
myeloma. In all patients with advanced acute myeloid
or acute lymphoid leukemia and in many with aggres-
sive NHL, early disease progression occurred. This
likely reﬂects the inadequate cytoreduction conferred
by cyclophosphamide and the inability to deliver
pDLI before the tumor had advanced to a level that
could not be controlled by DLI. It is likely that for
aggressive malignancies, additional drug(s) with both
immunosuppressive and cytoreductive properties to
facilitate engraftment and control tumor growth
might be needed in the conditioning regimen. How-
ever, enhanced transplant-related morbidity or more
GVHD could occur with such intensiﬁcation of con-
ditioning therapy. Using a reduced intensity regimen
of busulfan, ﬂudarabine, and ATG, Slavin et al. [34]
showed a 14-month survival rate of 77.4% in patients
with mainly standard-risk hematologic malignancies.
Among 26 patients, however, 15% succumbed to fatal
acute GVHD and hepatic veno-occlusive disease.
Other groups have used various combinations of ﬂu-
darabine with cyclophosphamide [35-37], including
many requiring dose escalation of conditioning che-
motherapy [38] to reduce graft rejection and to have
better impact on the disease remission.
Our cyclophosphamide-based nonmyeloablative
conditioning regimen for HLA-matched BMT re-
sulted in the reliable induction of initial MC. Al-
though it is difﬁcult to interpret the true effects of
pDLI without an adequate control group, pDLI given
after early cessation of GVHD prophylaxis has the
potential to convert MC to FDC and induce sustained
remission in patients with chemotherapy-refractory
hematologic malignancies, albeit with a signiﬁcant risk
of acute GVHD. It may, however, be important to
tailor the regimen to the underlying disease (indolent
versus aggressive) and to revise the schedule of pDLI
according to the patterns of chimerism (increasing or
decreasing at the time of pDLI). Our current strate-
gies are focusing on the optimization of in vivo T cell
depletion with MEDI-507 (a humanized CD2 mono-
clonal antibody) and possibly the addition of ex vivo T
cell depletion to achieve a GVHD-free environment
after the BMT before pDLI.
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